Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical
Registered with the Regional Ethics Committee (H-21045751), EudraCT (2021-002028-19), ClinicalTrials.gov (NCT05350592). Study registration date: 2022-03-08, Universal Trial Number U1111-1277-8523.
Authors
- Christian Hassager (ORCID: https://orcid.org/0000-0002-1199-0981)
- Helle Søholm (ORCID: https://orcid.org/0000-0002-0662-0898)
- Jakob Hartvig Thomsen (ORCID: https://orcid.org/0000-0002-6782-9599)
- Sebastian C. Wiberg (ORCID: https://orcid.org/0000-0002-7062-7189)
- Jesper Kjærgaard (ORCID: https://orcid.org/0000-0001-8493-2021)
- Martin Frydland (ORCID: https://orcid.org/0000-0003-1543-8948)
- Thomas Engstrøm (ORCID: https://orcid.org/0000-0001-5436-9194)
- Sarah Louise Duus Holle (ORCID: https://orcid.org/0000-0001-8426-617X)
- Pernille Palm (ORCID: https://orcid.org/0000-0002-8437-5445)
- Joakim Bo Kunkel (ORCID: https://orcid.org/0000-0002-0793-4557)
- Jacob Eifer Møller (ORCID: https://orcid.org/0000-0003-2873-5845)
- Lene Holmvang
- Redi Pecini
- Jacob Thomsen Lønborg
- Lia E. Bang
Institutions
- University of Copenhagen (DK)
- Frederiksberg Hospital (DK)
- Odense University Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Zealand University Hospital (DK)
Publication Details
- Journal
- Trials
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1186/s13063-024-08573-0
- Citations
- 9
- Primary Topic
- Acute Myocardial Infarction Research
- Type
- article
- Field-Weighted Citation Impact
- 3.62
Funders
- Københavns Universitet